Quantifying TV And Video's GLP-1 Ad Market

Amazon announced this week that the company will introduce a new GLP-1 program, becoming the latest entrant into the weight loss drug space.

What does the market Amazon's entering into already look like, though? At least from an ad perspective, it appears to be pretty robust as it is (and growing larger).

• iSpot data shows that GLP-1 ads accounted for $171.7 million in est. national linear TV ad spend in Q1 – which would be the No. 12 industry in the timeframe.
• For full-year 2025, GLP-1 brands spent an estimated $507 million on linear TV ads alone, which would be the No. 21 industry overall.
• Zepbound (Eli Lilly and Company) led the way last year among GLP-1 TV ads, with over $160 million estimated spend on national linear TV. Mounjaro (also Elil Lilly) and Ozempic (Novo Nordisk) both spent over $90 million last year.

And what about YouTube?

Tubular Labs data shows In the U.S. in Q1 2026, there were 27.8K videos published on YouTube about GLP-1s, totaling 503 million views.

Of those, 30% views came from brands (led by Ozempic and Wegovy), while 60% came from creators (nearly all of whom were unsponsored).

Ultimately, GLP-1s are a crowded space – there were at least 12 different GLP-1 drugs advertised on linear and/or streaming TV last year. But with more approvals coming, companies like Amazon jumping in, and some pivoting to oral medications, that pool is likely to get even more full.